The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...
Pediatric growth hormone deficiency (PGHD) is a genetic condition that affects your child’s physical development. Hormone replacement therapy can help promote growth, and a new injection now makes it ...
The Subject Expert Committee (SEC), which advises the drug regulator on endocrinology and metabolism segment, has recommended approval for import and marketing of Denmark-based Novo Nordisk's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results